Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

Table 1 Patient and clinical characteristics for all the 87 patients considered for analysis

Patient and clinical characteristics	Number of patients	Age (mean ± SD)	BMI (mean ± SD)
Chemotherapy and targeted therapies
T × 12/AC × 4	54	48.48 ± 11.52	29.89 ± 7.18
TCHP × 6	21	53.80 ± 10.04	29.307 ± 9.49
TC × 6	6	59.67 ± 12.24	30.54 ± 3.24
T/C × 12/AC × 4	4	39.25 ± 8.65	30.05 ± 2.29
TC × 4	1	30	18.11
THP × 12/AC × 4	1	40	32.23
Menopausal status
Premenopausal	52	41.65 ± 6.90	29.48 ± 7.91
Postmenopausal	34	61.63 ± 6.00	30.10 ± 6.82
Uncertain	1	56	27.16
Tumor characteristics	Number of tumors
Treatment response classification
pCR
RCB 0	36
Non-pCR
RCB I	10
RCB II	27
RCB III	11
RCB score not available	3

Abbreviations and acronyms: T × 12/AC × 4, 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth factor support; T/C × 12/AC × 4, 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with growth-factor support with an addition of carboplatin to paclitaxel; TC × 6, six cycles Cytoxan plus Taxotere; TC × 4, four cycles Cytoxan plus Taxotere; TCHP, six cycles of docetaxel, carboplatin, and trastuzumab plus pertuzumab; THP/AC, paclitaxel, trastuzumab, and pertuzumab followed by doxorubicin and cyclophosphamide; pCR, pathologic complete response; RCB, residual cancer burden; BMI, body mass index; SD, standard deviation

ISSN: 1465-542X